Colonics
About Me
Recent Posts
- 4 Mushroom Poisonings In 2 Weeks - Doctors Test Milk Thistle As Treatment
- Improved Diagnostics For Sleeping Sickness
- Prostate Growth May Be Slowed By Statins
- New Tools For Psychological Science Research - Facebook And Smartphones
- Finding That Oxytocin Improves Brain Function In Children With Autism Could Lead To Treatment For Associated Social Deficits
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
Friends
Links
Entry 1 of 2380
Last Page | Next Page
6/24/2011
-
Meeting Highlights From The Committee For Medicinal Products For Human Use (CHMP)
|
The organization adopted unbounded opinions recommending the granting of dealing authorisations for the coming new medicines: - Buccolam (midazolam), from ViroPharma SPRL, intended for the regimen of prolonged, acute, convulsive seizures in paediatric business from the age of 3 months to 18 years. The review for Buccolam began on 22 September 2010 with an active review time of 210 days. This is the first CHMP feeler for a paediatric-use dealing authorisation (PUMA). - Eurartesim (dihydroartemisinin/piperaquine phosphate), from Sigma-tau Industrie Farmaceutiche Riunite S.p.A...
More: - Continued here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
